Episode summary
Baylor Endowment on Rethinking Venture Capital, Concentrated Portfolios, and Power of Compounding
Summary
Baylor University’s private portfolio is built around a deliberately concentrated, liquidity-aware framework rather than a traditional venture power-law hunt. Renee Hanna says Baylor rebuilt the book from scratch starting in 2014 without legacy early-stage exposure, so it leaned into expansion capital, lower middle market buyouts, and selective later-stage venture where product-market fit and liquidity are clearer. She argues that Baylor is willing to accept capped upside if the path to a 3x to 5x return is more repeatable and durable.
A central thesis is that recurring 3x outcomes can beat a single 15x venture winner over time. Hanna says Baylor allocates about 30% of its private portfolio to expansion capital, because a steady 3x every 5 years can compound into a 27x outcome over 15 years. She contrasts that with early-stage investing, where higher entry prices, wider loss ratios, and longer holding periods make the math harder.
The episode also emphasizes portfolio concentration and manager concentration as sources of alpha. Baylor is intentionally narrowing its GP roster, increasing commitments to its best relationships, and using active portfolio management, follow-ons, and secondaries to trim weak positions and fund winners. Hanna says Baylor’s private investments must clear a 15% net IRR hurdle, and the firm prefers managers with specialization, conviction, and a clear line of sight to liquidity.
Key takeaways
- Renee Hanna says Baylor rebuilt its private portfolio without legacy venture positions, so it emphasized expansion capital and lower middle market exposure instead.
- Baylor allocates about 30% of its private portfolio to expansion capital and targets repeatable 3x to 5x returns in 3 to 5 years.
- Hanna says a repeatable 3x every 5 years can compound into a 27x outcome over 15 years, which she views as better than a single 15x venture win.
- Baylor requires roughly a 15% net IRR to justify private-market illiquidity and will sell underperforming assets early if the time cost is too high.
- The team has become more open to later-stage venture because product-market fit and clearer liquidity reduce downside versus pre-seed and seed investing.
Notable quotes
“we didn't have the benefit of having legacy exposure to early stage names”
“We're trying to construct a portfolio and so if I can get into a great name and it's only a $5 million check size on a $2.7 billion endowment, I'm not sure that I care”
“we have groups that have venture at the end of their name, but you look through to the underlying portfolio and it's comprised of eight to 10 companies”
“Anything coming into the private investment portfolio has a line in the sand of generating a 15% net IRR to justify the lack of liquidity”
Topics
- venture capital rethinking
- private market compounding
- portfolio concentration
- expansion capital
- downside protection
Watch the episode
Summary, takeaways and quote selection by Octagon. Quotes are short excerpts; the full conversation is in the episode.
More from How I Invest With David Weisburd
-
True Anomaly’s Even Rogers on Space Warfare, China’s Military Advantage, and the Defense Tech Boom -
Finding the Next Anthropic, Quantifying Venture Capital, and the Science of Picking Winners -
Why 95% of AI Projects Fail, Anthropic still at $2T?, and Why AI Is Still in the First Inning -
Peter Thiel's 27-Year Partner on the AI Bubble, the Venture Capital Crisis, and the PayPal Mafia -
Why Venture Is Eating Public Markets, Picking Great VCs, and the AI Boom w/Brijesh Jeevarathnam -
Federated Hermes CEO on $400 Billion in Cash, the Private Markets Boom, and AI
How I Invest With David Weisburd, this episode and its artwork belong to David Weisburd. Octagon is not affiliated with the show; this page is an independent summary.